Key Takeaways
- Volume-led recovery, margin inflection: Revenue rose 21% QoQ and EBITDA surged 36% QoQ, driven by operating leverage as volumes recovered across key products, with the benefit of cost-cutting initiatives still largely ahead.
- MMA delivers peak volumes, tariff headwinds managed: MMA achieved its highest-ever quarterly volumes, but US tariffs compressed margins and volumes; the lost US volume was actively placed in other geographies, arresting further downside.
- Zone 4 capex cycle nears harvest: The first multipurpose unit commissions next quarter, with five chemistry blocks to follow sequentially through FY27, shifting the narrative from investment to ramp-up and returns.
- Capital allocation pivots to discipline: Management declared the era of ₹1,000 crore-plus ticket-size projects over for now; focus shifts to medium-scale, quick-return projects leveraging existing infrastructure, with FY27 capex guided substantially lower.
- What to watch next quarter: Commissioning and initial offtake from the Zone 4 multipurpose plant, the pace of US volume resumption amid tariff negotiations, and whether the current volume run-rate sustains to deliver the promised operating leverage.
Volume Recovery & Operating Leverage
- Broad-based volume improvement: Revenue growth was driven by improved volumes across key product categories, with the portfolio converging in contribution profiles such that variation across end applications is no longer significant.
- Operating leverage is the margin engine: Contribution margins at the product portfolio level remain consistent; the EBITDA surge is predominantly a function of higher volumes flowing through a fixed-cost base.
- Steady-state assumption with ambition: Management indicated the current quarter's performance level can be assumed as steady-state if volumes are maintained, but stressed the objective is to improve further through volume ramp-up and cost optimization.
- Cost-cutting benefit still accruing: Actions for the ₹150-200 crore cost-cutting program are fully completed, but per an analyst's math roughly 40-50% of the benefit is yet to flow through, with major items like renewable power purchase agreements commissioning only in April 2026. The benefit is also volume-linked: as volumes increase, cost savings multiply.
- Working capital shift, not stress: The increase in debtor days reflects a higher export mix (exports now exceed 60% of revenue), where credit profiles are longer; overall working capital cycle remains stable at 45-50 days as inventory days have declined.
Kotecha: "The margin's improvement was predominantly driven by operating leverage. At a contribution level, if you see at the overall product portfolio level, we remain quite consistent on the contribution margin level. But as the overall business volume goes up, the operating leverage starts kicking in and that starts getting reflected in the EBITDA percentage increase."
MMA: Peak Volumes, Tariff Headwinds & Capacity Expansion
- Record quarterly volumes: MMA delivered its highest-ever quarterly volumes, driven by spill-over demand from Q1, diversification to new geographies with encouraging initial customer response, and favourable naphtha-to-gasoline spreads that supported robust blender consumption.
- US tariffs compressed performance: US tariffs weighed on both MMA volumes and margins; the share of US business in Q2 was significantly lower than Q1. Renegotiations with customers are underway as a proactive measure to secure future demand.
- No net revenue loss: Volume lost from the US was actively placed in other markets, offsetting the impact. Management expects resumption of US volumes this quarter despite ongoing tariff uncertainty.
- Debottlenecking underway: The newly expanded MMA capacities achieved peak utilisation; debottlenecking initiatives are executing to scale up volumes further from Q4 FY26. Management remains very confident about MMA market potential, citing one of the largest and most competitive capacities globally with several technology innovations.
- Competitive pressure persists: Ongoing competitive pricing challenges from both China and domestic Indian players remain a headwind.
- Regional mix in flux: Management declined to disclose the current GCC-versus-other split for MMA, stating it is driven by the geopolitical situation and expects a stable global footprint position in roughly six months, contingent on US-India trade resolution.
Kotecha: "As we see based on the current situation, it feels like China has a preferred trade arrangement even than India in today's situation. We hope that will change very soon."
Zone 4: Commissioning Timeline & Strategic Logic
- Multipurpose plant first, then chemistry blocks: The first unit to commission in Q3 FY26 is a multipurpose plant. Five subsequent blocks, each chemistry-oriented (photochlorination, hydrolysis, nitration, etc.), will commission sequentially over the course of FY27.
- PEDA as value-chain play: The new 4,000 TPA PEDA project in Zone 4 will utilise raw materials from the Ethylation capacity in Dahej, positioning Aarti as a key domestic supplier. Management views PEDA as an end-to-end value chain from aniline to ethylene, not a standalone product, and declined to share product-specific economics.
- Chlorotoluene value chain: All five Zone 4 blocks are designed to produce chlorotoluene derivatives and many other products; product selection will depend on market dynamics and contribution possibilities at the time.
- Ramp-up will be gradual: Products with well-developed markets will accrue to the bottom line relatively quickly, but many specialty products from Zone 4 blocks will take time to ramp up due to qualification cycles with global customers.
- Chlorine supply secured: A long-term strategic partnership with DCM Shriram secures exclusive chlorine supply from its Chlor-Alkali plant to Aarti's downstream chemicals facility at Zone 4.
- No take-or-pay contracts: Management confirmed that none of the upcoming projects are backed by customer take-or-pay contracts, noting the industry has moved past that phase.
Capital Allocation: The Pivot to Discipline
- Large-ticket capex cycle is over: Management explicitly stated they are not contemplating the next ₹1,000 crore-plus investment; the focus for the next few years is on digesting the capital expenditure of the last 2-3 years.
- Medium-scale, quick-return projects: Future capital allocation will target relatively medium ticket-size projects that can be turned around quickly based on existing infrastructure and significantly accrue to the bottom line, with no specific preference toward any particular application.
- FY27 capex substantially lower: Capex for FY26 remains guided at around ₹1,000 crore; FY27 capex will be substantially lower, though the exact number is not yet worked out.
- Debt-to-EBITDA peak likely behind: Management believes debt-to-EBITDA has potentially already peaked and should improve going forward, though some increase in finance cost will come through as projects kick in with limited initial EBITDA contribution.
Kotecha: "I do not think at this point in time, we are thinking about sort of the next level of large investment, which is sort of INR1,000 crore plus kind of a ticket size, which is what we did at Zone 4. I think for the next few years, the focus will remain on sort of relatively medium ticket size projects, which can be turned around quickly based on existing infrastructure, at the same time, significantly accrue to the bottom line."
End-Market & Segment Dynamics
| Segment | Trend | Commentary |
|---|---|---|
| MMA / Energy | ▲ Strong volumes | Record quarterly volumes; energy segment expected to settle at 30-40% of mix as Zone 4 ramps up over 1.5-2 years. |
| Agrochemicals | ▬ Mixed | Select products showing volume recovery, but overall margins remain under pressure; some second-order impact from downstream customers exporting to the US. Inventory-linked pressures mostly settled. |
| Dyes & Pigments | ▼ Muted | Demand growth has been muted. |
| Polymer | ▼ Headwind | Faced significant headwind as US tariffs impacted volumes. |
| Pharma | ▬ Stable | Domestic pharma market remains stable, providing a consistent base. |
| High-value Fluoro | ▼ Pressure | Margins experiencing notable challenges due to aggressive competitive pricing from China. |
- US market recalibration: The export mix was actively rebalanced toward Europe, Middle East, and Africa to offset US tariff impact. Ex-tariffs, the US typically enjoys a better margin profile than other geographies, so resolution of the India-US trade deal remains a positive catalyst.
- Broader recovery contingent on trade: Management anticipates gradual recovery through the next couple of years as global trade flows stabilise and pricing dynamics improve, with successful negotiation of a potential India-US trade deal as a major catalyst.
Innovation Pipeline: CDMO, MPP & R&D
- CDMO in early stages: Work has started with 3-4 projects at the R&D level, building relationships with global innovators. Converting these into concrete large-scale manufacturing business is an 18 to 24-month journey.
- Multipurpose plant as capability, not profit centre: The MPP is viewed as a flexible asset that reduces time-to-market for new innovative products significantly, rather than as a net contribution engine. Once a product is stabilised, Aarti can continue manufacturing in the MPP or build dedicated assets if volumes ramp up.
- PEDA as MPP proof case: PEDA exemplifies the MPP model: 80-90% of infrastructure already exists in the multipurpose plant, with final tweaking making the asset ready to deliver on a specific product in a specific value chain.
- R&D intensification: Efforts intensified in advanced materials, polymer chemistry, and other sunrise applications, with the shift toward innovation-led growth expected to become decisive as the current capex cycle concludes.
Kotecha: "The way we look at MPP is a flexible asset, which reduces our time to market for new innovative products significantly. So it is been looked at as a capability rather than necessarily as an NC or as a net contribution engine."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Zone 4 multipurpose plant commissioning | First unit in Zone 4 to be commissioned | Q3 FY26 (next quarter) |
| Calcium Chloride facility commissioning | Facility to be commissioned | Q3 FY26 (ongoing quarter) |
| MMA debottlenecking capacity | Slightly increased MMA capacity from debottlenecking | Q4 FY26 |
| PEDA project commissioning | 4,000 TPA PEDA project in Zone 4 | Not specified; set to commission |
| Zone 4 sequential block commissioning | 5 incremental chemistry blocks | Sequentially through FY27 |
| FY26 capex | Around ₹1,000 crore | FY26 |
| FY27 capex | Substantially lower than ₹1,000 crore | FY27 |
| Debt-to-EBITDA trajectory | Potentially already peaked; should improve | Going forward |
| Energy segment steady-state mix | Settle in 30-40% range | End of 2-2.5 years |
| CDMO commercialisation | R&D projects to large-scale manufacturing | 18-24 months |
| Cost-cutting benefit flow-through | Major items (renewable PPAs, RM contracts) yet to flow | Renewable PPAs: April 2026 |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | ₹2,250 cr, +21% QoQ |
| EBITDA | ₹292 cr, +36% QoQ |
| Profit After Tax | ₹106 cr, ~150% QoQ increase, after factoring in exceptional items |
| EBITDA margin | 13.0% (₹292 cr on ₹2,250 cr revenue, per analyst's math) |
| CAPEX (quarter) | ₹267 cr |
| CAPEX guidance (FY26) | ~₹1,000 cr |
| CAPEX guidance (FY27) | Substantially lower than ₹1,000 cr |
| Tax rate estimate (FY27) | Below 15% |
| Tax rate estimate (FY28) | Between 15% to 20% |
| Energy segment revenue share | 43% of revenue |
| Export share | Upwards of 60% of revenue |
| Working capital cycle | 45–50 days |
| Cost optimization program | ₹150–200 cr in actions completed, roughly 40–50% benefit yet to flow through to bottom line |
| MMA capacity debottlenecking target | ~3 lakh tons |
| PEDA new capacity | 4,000 TPA |